| Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled … DW Dodick, PJ Goadsby, SD Silberstein, RB Lipton, J Olesen, M Ashina, ... The lancet neurology 13 (11), 1100-1107, 2014 | 444 | 2014 |
| A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis … JL Vincent, MK Ramesh, D Ernest, SP LaRosa, J Pachl, N Aikawa, ... Critical care medicine 41 (9), 2069-2079, 2013 | 334 | 2013 |
| Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2 RB Lipton, PJ Goadsby, J Smith, BA Schaeffler, DM Biondi, J Hirman, ... Neurology 94 (13), e1365-e1377, 2020 | 330 | 2020 |
| Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1) M Ashina, J Saper, R Cady, BA Schaeffler, DM Biondi, J Hirman, ... Cephalalgia 40 (3), 241-254, 2020 | 321 | 2020 |
| Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial AL Boxer, AE Lang, M Grossman, DS Knopman, BL Miller, LS Schneider, ... The Lancet Neurology 13 (7), 676-685, 2014 | 290 | 2014 |
| Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial DW Dodick, RB Lipton, S Silberstein, PJ Goadsby, D Biondi, J Hirman, ... Cephalalgia 39 (9), 1075-1085, 2019 | 147 | 2019 |
| A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal … BH Morimoto, D Schmechel, J Hirman, A Blackwell, J Keith, M Gold, ... Dementia and geriatric cognitive disorders 35 (5-6), 325-339, 2013 | 110 | 2013 |
| Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial S Ständer, P Kwon, J Hirman, AJ Perlman, E Weisshaar, M Metz, ... Journal of the American Academy of Dermatology 80 (5), 1395-1402, 2019 | 98 | 2019 |
| Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a … LC Parish, JL Jorizzo, JJ Breton, JW Hirman, NE Scangarella, RM Shawar, ... Journal of the American Academy of Dermatology 55 (6), 1003-1013, 2006 | 95 | 2006 |
| Progression of brain atrophy in PSP and CBS over 6 months and 1 year S Dutt, RJ Binney, HW Heuer, P Luong, S Attygalle, P Bhatt, GA Marx, ... Neurology 87 (19), 2016-2025, 2016 | 84 | 2016 |
| Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 … S Silberstein, M Diamond, NA Hindiyeh, DM Biondi, R Cady, J Hirman, ... The journal of headache and pain 21, 1-12, 2020 | 76 | 2020 |
| Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: subgroup analysis of PROMISE‐2 HC Diener, MJ Marmura, SJ Tepper, R Cowan, AJ Starling, ML Diamond, ... Headache: The Journal of Head and Face Pain 61 (1), 125-136, 2021 | 66 | 2021 |
| Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin A Free, E Roth, M Dalessandro, J Hirman, N Scangarella, R Shawar, ... SKINmed: Dermatology for the clinician 5 (5), 224-232, 2006 | 63 | 2006 |
| Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial D Kudrow, RK Cady, B Allan, SM Pederson, J Hirman, LR Mehta, ... BMC neurology 21, 1-12, 2021 | 59 | 2021 |
| Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study TR Smith, M Janelidze, G Chakhava, R Cady, J Hirman, B Allan, ... Clinical therapeutics 42 (12), 2254-2265. e3, 2020 | 44 | 2020 |
| Dysregulation of inflammatory and hemostatic markers in sepsis and suspected disseminated intravascular coagulation D Hoppensteadt, K Tsuruta, J Hirman, I Kaul, Y Osawa, J Fareed Clinical and Applied Thrombosis/Hemostasis 21 (2), 120-127, 2015 | 39 | 2015 |
| Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin D Hoppensteadt, K Tsuruta, J Cunanan, J Hirman, I Kaul, Y Osawa, ... Clinical and Applied Thrombosis/Hemostasis 20 (2), 129-135, 2014 | 39 | 2014 |
| Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing DW Dodick, C Gottschalk, R Cady, J Hirman, J Smith, S Snapinn Headache: The Journal of Head and Face Pain 60 (10), 2220-2231, 2020 | 38 | 2020 |
| Primary results of PROMISE-1 (prevention of migraine via intravenous eptinezumab safety and efficacy–1) trial: a phase 3, randomized, double-blind, placebo-controlled study to … J Saper, R Lipton, D Kudrow, J Hirman, D Dodick, S Silberstein, ... Neurology 90 (15 Supplement), 2018 | 38 | 2018 |
| A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab in frequent episodic migraine prevention: primary results of … J Saper, R Lipton, D Kudrow, J Hirman, D Dodick, S Silberstein, ... Cephalalgia 37, 337-337, 2017 | 32 | 2017 |
